Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary gland of rats.

Abstract

It is shown that daily oral administration of 5--10 mg of an antidiabetic biguanide-phenformin (phenethyl-biguanide) for 2.5--5 months suppressed DMBA-induced mammary tumour development in rats considerably. Phenformin-treated rats revealed-a tendency towards a decrease in blood insulin level (radioimmunoassay). The obtained data are regarded as additional evidence for the proposed existence of the same metabolic background of diseases of compensation, i.e. adult-onset diabetes, artherosclerosis and cancer, and suggest studies on possible antitumour effect of phenformin in man.

• Authors: V M Dilman, L M Berstein, M A Zabezhinski, V A Alexandrov, J F Bobrov, G B Pliss
• Journal: Archiv fur Geschwulstforschung (Arch Geschwulstforsch) Vol. 48 Issue 1 Pg. 1-8 ( 1978) ISSN: 0003-911X [Print] Germany
• PMID: 418748 (Publication Type: Journal Article)

Chemical References

• Blood Glucose
• Fatty Acids, Nonesterified
• Insulin
• 9,10-Dimethyl-1,2-benzanthracene
• Cholesterol
• Phenformin

Topics

• 9,10-Dimethyl-1,2-benzanthracene
• Animals
• Blood Glucose (analysis)
• Cholesterol (blood)
• Fatty Acids, Nonesterified (blood)
• Insulin (blood)
• Mammary Neoplasms, Experimental (prevention & control)
• Phenformin (therapeutic use)
• Rats